


Intratumoral delivery of genetically engineered anti-IL-6 trans-signaling therapeutics

Online Resource 2



Online Resource 2 a) Tumor progression in groups treated with either sgp130Fc-secreting HEK cells or control HEK cells. Tumor volumes were monitored and recorded at indicated time-points

b) Survival curves were generated based on time to reach humane endpoint criteria. Curves show slightly higher animal survival in treated group (n=6 per group)